Magazine
Oncolytics Biotech (ONCY) — Pelareorep, GI focus, catalysts into Q1–H1 2026 | Oncolytics Biotech (ONCY) — Pelareorep, focus GI, catalyst Q1–H1 2026 EN IT Oncolytics Biotech (ONCY) Panel-style report (EN/IT): news-first, catalyst timelines, fundamentals/cash runway, pipeline, management/ownership, retail sentiment, risk map, and sources. Latest key update Read first FDA alignment on pivotal Phase 3 design […]
I suoi ultimi articoli
-
Indivior $INDV: SUBLOCADE Growth Meets the Supernus Merger
-
Lithium Argentina $LAR: Production, Expansion and Risk
-
Le azioni di compagnie aeree e turismo rimbalzano mentre le speranze di pace spingono il petrolio più in basso: perché $AAL, $UAL, $DAL e $CCL tornano sul radar
-
La tregua che cambia il mercato: l’intesa USA-Iran riapre il caso Hormuz
